{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:54:27Z","timestamp":1790380467360,"version":"4.1.0"},"reference-count":142,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T00:00:00Z","timestamp":1563235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades, Spain.","award":["PSI2017-83023"],"award-info":[{"award-number":["PSI2017-83023"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Currently, there are no approved pharmacotherapies for addiction to cocaine and other psychostimulant drugs. Several studies have proposed that cannabidiol (CBD) could be a promising treatment for substance use disorders. In the present work, the authors describe the scarce preclinical and human research about the actions of CBD on the effects of stimulant drugs, mainly cocaine and methamphetamine (METH). Additionally, the possible mechanisms underlying the therapeutic potential of CBD on stimulant use disorders are reviewed. CBD has reversed toxicity and seizures induced by cocaine, behavioural sensitization induced by amphetamines, motivation to self-administer cocaine and METH, context- and stress-induced reinstatement of cocaine and priming-induced reinstatement of METH seeking behaviours. CBD also potentiated the extinction of cocaine- and amphetamine-induced conditioned place preference (CPP), impaired the reconsolidation of cocaine CPP and prevented priming-induced reinstatement of METH CPP. Observational studies suggest that CBD may reduce problems related with crack-cocaine addiction, such as withdrawal symptoms, craving, impulsivity and paranoia (Fischer et al., 2015). The potential mechanisms involved in the protective effects of CBD on addiction to psychostimulant drugs include the prevention of drug-induced neuroadaptations (neurotransmitter and intracellular signalling pathways changes), the erasure of aberrant drug-memories, the reversion of cognitive deficits induced by psychostimulant drugs and the alleviation of mental disorders comorbid with psychostimulant abuse. Further, preclinical studies and future clinical trials are necessary to fully evaluate the potential of CBD as an intervention for cocaine and methamphetamine addictive disorders.<\/jats:p>","DOI":"10.3390\/molecules24142583","type":"journal-article","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T02:44:03Z","timestamp":1563331443000},"page":"2583","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Cannabidiol Treatment Might Promote Resilience to Cocaine and Methamphetamine Use Disorders: A Review of Possible Mechanisms"],"prefix":"10.3390","volume":"24","author":[{"given":"Claudia","family":"Calpe-L\u00f3pez","sequence":"first","affiliation":[{"name":"Unit of Research \u201cNeurobehavioural mechanisms and endophenotypes of addictive behavior\u201d, Department of Psychobiology, University of Valencia, Avda. Blasco Iba\u00f1ez 21, 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Pilar","family":"Garc\u00eda-Pardo","sequence":"additional","affiliation":[{"name":"Department of Psychology and Sociology, University of Zaragoza, 44003 Teruel, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1935-6619","authenticated-orcid":false,"given":"Maria A.","family":"Aguilar","sequence":"additional","affiliation":[{"name":"Unit of Research \u201cNeurobehavioural mechanisms and endophenotypes of addictive behavior\u201d, Department of Psychobiology, University of Valencia, Avda. Blasco Iba\u00f1ez 21, 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,7,16]]},"reference":[{"key":"ref_1","unstructured":"(2019, April 05). European Monitoring Centre for Drugs and Drug Addiction, European Drug Report 2018: Trends and Developments, Publications Office of the European Union, Luxembourg. Available online: http:\/\/www.emcdda.europa.eu\/system\/files\/publications\/8585\/20181816_TDAT18001ENN_PDF.pdf."},{"key":"ref_2","unstructured":"(2019, April 05). World Drug Report 2018 (United Nations publication, Sales No. E.18.XI.9). Available online: https:\/\/www.unodc.org\/wdr2018\/prelaunch\/WDR18_Booklet_4_YOUTH.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejphar.2016.03.040","article-title":"Advances and challenges in pharmacotherapeutics for amphetamine-type stimulants addiction","volume":"780","author":"Cao","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/13543784.2017.1313229","article-title":"Pharmacotherapeutic agents in the treatment of methamphetamine dependence","volume":"26","author":"Morley","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/YCO.0000000000000518","article-title":"Medications to treat cocaine use disorders: Current options","volume":"32","author":"Buchholz","year":"2019","journal-title":"Curr. Opin. Psychiatry"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0009-3084(02)00144-5","article-title":"Cannabidiol: An overview of some chemical and pharmacological aspects. Part I: Chemical aspects","volume":"121","author":"Mechoulam","year":"2002","journal-title":"Chem. Phys. Lipids"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1002\/j.1552-4604.2002.tb05998.x","article-title":"Cannabidiol: An overview of some pharmacological aspects","volume":"42","author":"Mechoulam","year":"2002","journal-title":"J. Clin. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1038\/sj.bjp.0706406","article-title":"Cannabinoid pharmacology: The first 66 years","volume":"147","author":"Pertwee","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.tips.2009.07.006","article-title":"Non-psychotropic plant cannabinoids: New therapeutic opportunities from an ancient herb","volume":"30","author":"Izzo","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","article-title":"Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro","volume":"150","author":"Thomas","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/bph.14440","article-title":"Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors","volume":"176","author":"Tham","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1017\/S1461145712001502","article-title":"The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: Involvement of the endocannabinoid system","volume":"16","author":"Campos","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-neuro-070815-014038","article-title":"Beyond the CB1 receptor: Is cannabidiol the answer for disorders of motivation?","volume":"39","author":"Zlebnik","year":"2016","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1124\/mol.118.111864","article-title":"Cannabidiol inhibits endocannabinoid signaling in autaptic hippocampal neurons","volume":"94","author":"Straiker","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2174\/157488611798280924","article-title":"Safety and side effects of cannabidiol, a Cannabis sativa constituent","volume":"6","author":"Bergamaschi","year":"2011","journal-title":"Curr. Drug Saf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pharmthera.2017.02.041","article-title":"Cannabidiol: State of the art and new challenges for therapeutic applications","volume":"175","author":"Pisanti","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","article-title":"Agonistic properties of cannabidiol at 5-HT1a receptors","volume":"30","author":"Russo","year":"2005","journal-title":"Neurochem. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00213-008-1168-x","article-title":"Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats","volume":"199","author":"Campos","year":"2008","journal-title":"Psychopharmacology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/jpet.109.162594","article-title":"The nonpsychoactive cannabinoid cannabidiol inhibits 5-hydroxytryptamine3A receptor-mediated currents in Xenopus laevisoocytes","volume":"333","author":"Yang","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Al Kury, L.T., Mahgoub, M., Howarth, F.C., and Oz, M. (2018). Natural Negative Allosteric Modulators of 5-HT\u2083 Receptors. Molecules, 23.","DOI":"10.3390\/molecules23123186"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ejphar.2013.10.011","article-title":"Effects of cannabidiol on the function of alpha7-nicotinic acetylcholine receptors","volume":"720","author":"Mahgoub","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00210-006-0033-x","article-title":"Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors","volume":"372","author":"Kathmann","year":"2006","journal-title":"Arch. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e920","DOI":"10.1038\/tp.2016.195","article-title":"Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose","volume":"6","author":"Seeman","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide","volume":"134","author":"Bisogno","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6231","DOI":"10.1523\/JNEUROSCI.0504-08.2008","article-title":"TRPV2 Is Activated by Cannabidiol and Mediates CGRP Release in Cultured Rat Dorsal Root Ganglion Neurons","volume":"28","author":"Qin","year":"2008","journal-title":"J. Neurosci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3389\/fnmol.2018.00487","article-title":"Cannabinoid Ligands Targeting TRP Channels","volume":"11","author":"Muller","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000201556","article-title":"The nonpsychotropic cannabinoid cannabidiol modulates and directly activates alpha-1 and alpha-1-Beta glycine receptor function","volume":"83","author":"Ahrens","year":"2009","journal-title":"Pharmacology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"16511","DOI":"10.1073\/pnas.0902743106","article-title":"The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo","volume":"106","author":"Ryberg","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bbrc.2017.05.165","article-title":"GPR3 and GPR6, novel molecular targets for cannabidiol","volume":"490","author":"Laun","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s41401-018-0031-9","article-title":"GPR3, GPR6, and GPR12 as novel molecular targets: Their biological functions and interaction with cannabidiol","volume":"40","author":"Laun","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1089\/can.2016.0034","article-title":"An update on safety and side effects of cannabidiol: A review of clinical data and relevant animal studies","volume":"2","author":"Iffland","year":"2017","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","article-title":"A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects","volume":"32","author":"Taylor","year":"2018","journal-title":"CNS Drugs"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1369-1600.2012.00483.x","article-title":"Cannabidiol inhibits the reward-facilitating effect of morphine: Involvement of 5-HT1A receptors in the dorsal raphe nucleus","volume":"2","author":"Katsidoni","year":"2013","journal-title":"Addict. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drugalcdep.2016.11.030","article-title":"Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers","volume":"172","author":"Babalonis","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s00213-004-1825-7","article-title":"Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats","volume":"175","author":"Parker","year":"2004","journal-title":"Psychopharmacology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41401-018-0032-8","article-title":"Cannabidiol does not display drug abuse potential in mice behavior","volume":"40","author":"Navarrete","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1089\/can.2018.0006","article-title":"A Cross-Sectional Study of Cannabidiol Users","volume":"3","author":"Corroon","year":"2018","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.3389\/fimmu.2018.02009","article-title":"Translational Investigation of the therapeutic potential of cannabidiol (CBD): Toward a new age","volume":"9","author":"Crippa","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_42","first-page":"33","article-title":"Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence","volume":"9","author":"Cata","year":"2015","journal-title":"Subst. Abuse"},{"key":"ref_43","unstructured":"Preedy, V.P. (2017). Cannabidiol for the treatment of drug use disorders. Handbook of Cannabis and Related Pathologies, Elsevier."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.tins.2016.12.006","article-title":"Cannabidiol: Swinging the marijuana pendulum from \u2018weed\u2019 to medication to treat the opioid epidemic","volume":"40","author":"Hurd","year":"2017","journal-title":"Trends Neurosci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3389\/fpsyt.2019.00063","article-title":"The Endocannabinoid System and Cannabidiol\u2019s Promise for the Treatment of Substance Use Disorder","volume":"10","author":"Chye","year":"2019","journal-title":"Front. Psychiatry"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/acer.13964","article-title":"Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review","volume":"43","author":"Turna","year":"2019","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"ref_47","first-page":"35","article-title":"Cocaine N-demethylation and the metabolism-related hepatotoxicity can be prevented by cytochrome P450 3A inhibitors","volume":"270","author":"Pellinen","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1006\/taap.1998.8403","article-title":"Effect of cytochrome P450 inducers on cocaine-mediated hepatotoxicity","volume":"150","author":"Bornheim","year":"1998","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0006-2952(01)00616-5","article-title":"Cannabinoid-induced alterations in brain disposition of drugs of abuse","volume":"61","author":"Reid","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0091-3057(90)90057-O","article-title":"Strain, sex and developmental profiles of cocaine metabolizing enzymes in mice","volume":"37","author":"Leibman","year":"1990","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"523418","DOI":"10.1155\/2015\/523418","article-title":"Cannabidiol rescues acute hepatic toxicity and seizure induced by cocaine","volume":"2015","author":"Vilela","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.neuro.2015.08.007","article-title":"Cannabidiol, a Cannabis sativa constituent, inhibits cocaine-induced seizures in mice: Possible role of the mTOR pathway and reduction in glutamate release","volume":"50","author":"Gobira","year":"2015","journal-title":"Neurotoxicology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1038\/sj.npp.1301648","article-title":"Context-specific reversal of cocaine sensitization by the CB1 cannabinoid receptor antagonist rimonabant","volume":"33","author":"Gerdeman","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.neuropharm.2018.09.043","article-title":"Repeated Cannabidiol treatment reduces cocaine intake and modulates neural proliferation and CB1R expression in the mouse hippocampus","volume":"143","author":"Valverde","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.alcohol.2017.06.004","article-title":"THC inhibits the expression of ethanol-induced locomotor sensitization in mice","volume":"65","author":"Filev","year":"2017","journal-title":"Alcohol"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1523\/JNEUROSCI.3387-15.2016","article-title":"Cannabidiol counteracts amphetamine-induced neuronal and behavioral sensitization of the mesolimbic dopamine pathway through a novel mTOR\/p70S6 kinase signaling pathway","volume":"36","author":"Renard","year":"2016","journal-title":"J. Neurosci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/0269881116667706","article-title":"Effects of an acute cannabidiol treatment on cocaine self-administration and cue-induced cocaine seeking in male rats","volume":"31","author":"Mahmud","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1177\/0269881118799954","article-title":"Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats","volume":"32","author":"Hay","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1038\/s41386-018-0050-8","article-title":"Unique treatment potential of cannabidiol for the prevention of relapse to drug use: Preclinical proof of principle","volume":"43","author":"Kerr","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/adb.12366","article-title":"Cannabidiol disrupts the reconsolidation of contextual drug-associated memories in Wistar rats","volume":"22","author":"Takahashi","year":"2017","journal-title":"Addict. Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.pnpbp.2017.08.022","article-title":"Cannabidiol inhibits priming-induced reinstatement of methamphetamine in REM sleep deprived rats","volume":"82","author":"Haghparast","year":"2018","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.drugpo.2015.09.005","article-title":"Addressing the stimulant treatment gap: A call to investigate the therapeutic benefits potential of cannabinoids for crack-cocaine use","volume":"26","author":"Fischer","year":"2015","journal-title":"Int. J. Drug Policy"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.addbeh.2017.04.006","article-title":"Intentional cannabis use to reduce crack cocaine use in a Canadian setting: A longitudinal analysis","volume":"72","author":"Kerr","year":"2017","journal-title":"Addict. Behav."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.addbeh.2017.03.025","article-title":"Cannabis and cue-induced craving in cocaine-dependent individuals: A pilot study","volume":"73","author":"Potvin","year":"2017","journal-title":"Addict. Behav."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.lfs.2011.01.013","article-title":"Effects on sleep and dopamine levels of microdialysis perfusion of cannabidiol into the lateral hypothalamus of rats","volume":"88","author":"Mechoulam","year":"2011","journal-title":"Life Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.neures.2014.04.006","article-title":"Intrahypothalamic injection of cannabidiol increases the extracellular levels of adenosine in nucleus accumbens in rats","volume":"84","year":"2014","journal-title":"Neurosci. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.lfs.2004.01.015","article-title":"Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum","volume":"75","author":"Zuardi","year":"2004","journal-title":"Life Sci."},{"key":"ref_68","first-page":"3369","article-title":"Effects of cannabidiol plus naltrexone on motivation and ethanol consumption","volume":"75","author":"Manzanares","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1007\/s00213-015-3945-7","article-title":"Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine","volume":"232","author":"Pedrazzi","year":"2015","journal-title":"Psychopharmacology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.neubiorev.2017.02.006","article-title":"Neuronal and molecular effects of cannabidiol on the mesolimbic dopamine system: Implications for novel schizophrenia treatments","volume":"75","author":"Renard","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1177\/0269881109106925","article-title":"Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania","volume":"25","author":"Valvassori","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"14764","DOI":"10.1523\/JNEUROSCI.4291-09.2009","article-title":"Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances","volume":"29","author":"Ren","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/bph.12944","article-title":"Are cannabidiol and \u0394(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review","volume":"172","author":"McPartland","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.brainres.2012.01.030","article-title":"The effects of cannabinoid CB1, CB2 and vanilloid TRPV1 receptor antagonists on cocaine addictive behavior in rats","volume":"1444","author":"Adamczyk","year":"2012","journal-title":"Brain Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neuropharm.2015.12.017","article-title":"Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT\/glutamate neurotransmission: Role of 5-HT1A receptors","volume":"103","author":"Linge","year":"2016","journal-title":"Neuropharmacology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.bbr.2014.04.007","article-title":"The role of serotonin in drug use and addiction","volume":"277","author":"Homberg","year":"2015","journal-title":"Behav. Brain Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.drugalcdep.2013.01.003","article-title":"Efficacy of buspirone for attenuating cocaine and methamphetamine reinstatement in rats","volume":"129","author":"Shelton","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.neuropharm.2006.06.001","article-title":"Attenuation by the 5-HT1A receptor agonist osemozotan of the behavioral effects of single and repeated methamphetamine in mice","volume":"51","author":"Ago","year":"2006","journal-title":"Neuropharmacology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.neuroscience.2010.05.040","article-title":"Pharmacological, neurochemical, and behavioral profile of JB-788, a new 5-HT1A agonist","volume":"169","author":"Picard","year":"2010","journal-title":"Neuroscience"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pneurobio.2007.01.001","article-title":"Serotonin and psychostimulant addiction: Focus on 5-HT1A-receptors","volume":"81","author":"Carey","year":"2007","journal-title":"Prog. Neurobiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.biopsych.2006.04.010","article-title":"Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse","volume":"61","author":"Feltenstein","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00213-009-1671-8","article-title":"Repeated aripiprazole administration attenuates cocaine seeking in a rat model of relapse","volume":"207","author":"Feltenstein","year":"2009","journal-title":"Psychopharmacology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00213-008-1069-z","article-title":"Aripiprazole blocks acute self-administration of cocaine and is not self-administered in mice","volume":"199","author":"Sager","year":"2008","journal-title":"Psychopharmacology"},{"key":"ref_84","first-page":"1231","article-title":"Characterization of the effects of the partial dopamine agonist terguride on cocaine self-administration in the rat","volume":"286","author":"Pulvirenti","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1369-1600.2010.00223.x","article-title":"Attenuation of reinforcing and psychomotor stimulant effects of amphetamine by aripiprazole","volume":"16","year":"2011","journal-title":"Addict. Biol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1038\/sj.npp.1301353","article-title":"Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration","volume":"32","author":"Wee","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s002130000384","article-title":"Effects of methyllycaconitine (MLA), an alpha 7 nicotinic receptor antagonist, on nicotine- and cocaine-induced potentiation of brain stimulation reward","volume":"149","author":"Panagis","year":"2000","journal-title":"Psychopharmacology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00213-006-0419-y","article-title":"Inhibition of both alpha7* and beta2* nicotinic acetylcholine receptors is necessary to prevent development of sensitization to cocaine-elicited increases in extracellular dopamine levels in the ventral striatum","volume":"187","author":"Zanetti","year":"2006","journal-title":"Psychopharmacology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1124\/jpet.105.089748","article-title":"Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum: Involvement of alpha7 nicotinic receptors","volume":"315","author":"Escubedo","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/j.1476-5381.2012.02043.x","article-title":"The orphan receptor GPR3 modulates the early phases of cocaine reinforcement","volume":"167","author":"Tourino","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.imbio.2009.09.007","article-title":"Cannabinoid activation of peroxisome proliferator-activated receptors: Potential for modulation of inflammatory disease","volume":"215","author":"Kendall","year":"2010","journal-title":"Immunobiology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/bph.13497","article-title":"An update on PPAR activation by cannabinoids","volume":"173","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.npp.1301213","article-title":"Peroxisome proliferator-activated receptor gamma activation relieves expression of behavioral sensitization to methamphetamine in mice","volume":"32","author":"Maeda","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/add.13868","article-title":"PPAR-gamma agonist pioglitazone modifies craving intensity and brain white matter integrity in patients with primary cocaine use disorder: A double-blind randomized controlled pilot trial","volume":"112","author":"Schmitz","year":"2017","journal-title":"Addiction"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.drugalcdep.2017.08.003","article-title":"Glial and neuroinflammatory targets for treating substance use disorders","volume":"180","author":"Bachtell","year":"2017","journal-title":"Drug Alcohol. Depend."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.bbi.2011.03.003","article-title":"Induction of innate immune genes in brain create the neurobiology of addiction","volume":"25","author":"Crews","year":"2011","journal-title":"Brain Behav. Immun."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.bbi.2017.08.012","article-title":"Innate immune signaling in the ventral tegmental area contributes to drug-primed reinstatement of cocaine seeking","volume":"67","author":"Brown","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Karimi-Haghighi, S., Dargahi, L., and Haghparast, A. (2019). Cannabidiol modulates the expression of neuroinflammatory factors in stress -and drug- induced reinstatement of methamphetamine in extinguished rats. Addict. Biol.","DOI":"10.1111\/adb.12740"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Kozela, E., Juknat, A., and Vogel, Z. (2017). Modulation of Astrocyte Activity by Cannabidiol, a Nonpsychoactive Cannabinoid. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18081669"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.bbi.2018.11.003","article-title":"Anti-inflammatory agents for smoking cessation? Focus on cognitive deficits associated with nicotine withdrawal in male mice","volume":"75","author":"Saravia","year":"2019","journal-title":"Brain Behav. Immun."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1111\/bph.13724","article-title":"Cannabidiol regulation of emotion and emotional memory processing: Relevance for treating anxiety-related and substance abuse disorders","volume":"174","author":"Lee","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.neuroscience.2017.07.018","article-title":"Effects of Cannabinoid Drugs on Aversive or Rewarding Drug-Associated Memory Extinction and Reconsolidation","volume":"370","author":"Stern","year":"2018","journal-title":"Neuroscience"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.conb.2012.11.008","article-title":"Drink, drugs and disruption: Memory manipulation for the treatment of addiction","volume":"23","author":"Milton","year":"2013","journal-title":"Curr. Opin. Neurobiol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3389\/fnins.2018.00502","article-title":"Cannabidiol as a Therapeutic Alternative for Post-traumatic Stress Disorder: From Bench Research to Confirmation in Human Trials","volume":"12","author":"Bitencourt","year":"2018","journal-title":"Front. Neurosci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1038\/npp.2012.63","article-title":"On disruption of fear memory by reconsolidation blockade: Evidence from cannabidiol treatment","volume":"37","author":"Stern","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3389\/fphar.2016.00493","article-title":"Bidirectional Effects of Cannabidiol on Contextual Fear Memory Extinction","volume":"7","author":"Song","year":"2016","journal-title":"Front. Pharmacol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3389\/fphar.2016.00454","article-title":"Cannabidiol Regulation of Learned Fear: Implications for Treating Anxiety-Related Disorders","volume":"7","author":"Jurkus","year":"2016","journal-title":"Front. Pharmacol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Gazarini, L., Stern, C.A., Piornedo, R.R., Takahashi, R.N., and Bertoglio, L.J. (2014). PTSD-like memory generated through enhanced noradrenergic activity is mitigated by a dual step pharmacological intervention targeting its reconsolidation. Int. J. Neuropsychopharmacol., 18.","DOI":"10.1093\/ijnp\/pyu026"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/ADM.0000000000000066","article-title":"Cocaine and cognition: A systematic quantitative review","volume":"8","author":"Potvin","year":"2014","journal-title":"J. Addict. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.drugalcdep.2018.08.041","article-title":"Methamphetamine use and cognitive function: A systematic review of neuroimaging research","volume":"194","author":"Sabrini","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1080\/15504263.2016.1146383","article-title":"Cognitive Function as a Transdiagnostic Treatment Target in Stimulant Use Disorders","volume":"12","author":"Sofuoglu","year":"2016","journal-title":"J. Dual Diagn."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/bs.pbr.2015.07.022","article-title":"Perspectives on neurocognitive rehabilitation as an adjunct treatment for addictive disorders: From cognitive improvement to relapse prevention","volume":"224","author":"Rezapour","year":"2016","journal-title":"Prog. Brain Res."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Aso, E., Fern\u00e1ndez-Due\u00f1as, V., L\u00f3pez-Cano, M., Taura, J., Watanabe, M., Ferrer, I., Luj\u00e1n, R., and Ciruela, F. (2019). Adenosine A2A-Cannabinoid CB1 Receptor Heteromers in the Hippocampus: Cannabidiol Blunts \u03949-Tetrahydrocannabinol-Induced Cognitive Impairment. Mol. Neurobiol.","DOI":"10.1007\/s12035-018-1456-3"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1089\/can.2017.0043","article-title":"Therapeutic effects of prolonged cannabidiol treatment on psychological symptoms and cognitive function in regular cannabis users: A pragmatic open-label clinical trial","volume":"3","author":"Solowij","year":"2018","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"7568","DOI":"10.1038\/s41598-018-25846-2","article-title":"The effects of cannabidiol on impulsivity and memory during abstinence in cigarette dependent smokers","volume":"8","author":"Hindocha","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/npp.2009.184","article-title":"Opposite effects of 1-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology","volume":"35","author":"Bhattacharyya","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ynstr.2018.08.003","article-title":"Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework","volume":"9","author":"Greenwald","year":"2018","journal-title":"Neurobiol. Stress"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","article-title":"Cannabidiol as a Potential Treatment for Anxiety Disorders","volume":"12","author":"Blessing","year":"2015","journal-title":"Neurotherapeutics"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2174\/1570159X14666160509123955","article-title":"Evidences for the Anti-panic Actions of Cannabidiol","volume":"15","author":"Soares","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1017\/S2045796018000239","article-title":"Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: A critical overview","volume":"27","author":"Mandolini","year":"2018","journal-title":"Epidemiol. Psychiatr. Sci."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1098\/rstb.2011.0389","article-title":"Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders","volume":"367","author":"Campos","year":"2012","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00213-018-5127-x","article-title":"Tempering aversive\/traumatic memories with cannabinoids: A review of evidence from animal and human studies","volume":"236","author":"Lisboa","year":"2019","journal-title":"Psychopharmacology"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00213-011-2415-0","article-title":"Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), \u0394\u2079-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour","volume":"219","author":"Deiana","year":"2012","journal-title":"Psychopharmacology"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00213-017-4819-y","article-title":"Do psychoactive drugs have a therapeutic role in compulsivity? Studies on schedule-induced polydipsia","volume":"235","author":"Mora","year":"2018","journal-title":"Psychopharmacology"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00213-017-4551-7","article-title":"A comparison of psychotic symptoms in subjects with methamphetamine versus cocaine dependence","volume":"234","author":"Alexander","year":"2017","journal-title":"Psychopharmacology"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3389\/fphar.2016.00422","article-title":"Cannabidiol as a potential new type of an antipsychotic. A critical review of the evidence","volume":"7","author":"Rohleder","year":"2016","journal-title":"Front. Pharmacol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.schres.2015.01.015","article-title":"Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol","volume":"164","author":"Gomes","year":"2015","journal-title":"Schizophr. Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00213-017-4766-7","article-title":"Phytocannabinoids modulate emotional memory processing through interactions with the ventral hippocampus and mesolimbic dopamine system: Implications for neuropsychiatric pathology","volume":"235","author":"Hudson","year":"2018","journal-title":"Psychopharmacology"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1515\/revneuro-2017-0101","article-title":"Cannabidiol effects on prepulse inhibition in nonhuman primates","volume":"30","author":"Saletti","year":"2018","journal-title":"Rev. Neurosci."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/sj.npp.1300838","article-title":"Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice","volume":"31","author":"Long","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.pbb.2010.03.004","article-title":"Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.","volume":"95","author":"Ivey","year":"2010","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pnpbp.2018.06.002","article-title":"Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels","volume":"86","author":"Sales","year":"2018","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1007\/s12035-018-1143-4","article-title":"Cannabidiol Induces Rapid and Sustained Antidepressant-Like Effects Through Increased BDNF Signaling and Synaptogenesis in the Prefrontal Cortex","volume":"56","author":"Sales","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1177\/0269881118784877","article-title":"Hippocampal mammalian target of rapamycin is implicated in stress-coping behavior induced by cannabidiol in the forced swim test","volume":"32","author":"Sartim","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1476-5381.2009.00521.x","article-title":"Antidepressant-like effects of cannabidiol in mice: Possible involvement of 5-HT1A receptors","volume":"159","author":"Zanelati","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1601-5215.2011.00579.x","article-title":"Administration of cannabidiol and imipramine induces antidepressant-like effects in the forced swimming test and increases brain-derived neurotrophic factor levels in the rat amygdala","volume":"23","author":"Stringari","year":"2011","journal-title":"Acta Neuropsychiatr."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.bbr.2016.01.033","article-title":"Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex-Possible involvement of 5-HT1A and CB1 receptors","volume":"303","author":"Sartim","year":"2016","journal-title":"Behav. Brain Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.pnpbp.2015.06.017","article-title":"Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice","volume":"64","author":"Schiavon","year":"2016","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.physbeh.2018.12.019","article-title":"Effects of cannabidiol in males and females in two different rat models of depression","volume":"201","author":"Shbiro","year":"2019","journal-title":"Physiol. Behav."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2174\/1871527313666140612114838","article-title":"Antidepressant-like and anxiolytic-like effects of cannabidiol: A chemical compound of Cannabis sativa","volume":"13","author":"Coutinho","year":"2014","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1021\/acschemneuro.7b00508","article-title":"Functional Relevance of Endocannabinoid-Dependent Synaptic Plasticity in the Central Nervous System","volume":"9","author":"Augustin","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/bs.pbr.2017.07.013","article-title":"Corticostriatal plasticity, neuronal ensembles, and regulation of drug-seeking behavior","volume":"235","author":"Bobadilla","year":"2017","journal-title":"Prog. Brain Res."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/14\/2583\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:06:11Z","timestamp":1760187971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/14\/2583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,16]]},"references-count":142,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2019,7]]}},"alternative-id":["molecules24142583"],"URL":"https:\/\/doi.org\/10.3390\/molecules24142583","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,16]]}}}